Developer docs
API playgroundTry for free, no card

Search company profiles

Verge Genomics

Full company profile

uuid00006a9

Namestring
Verge Genomics
Legal namestring
Verge Labs
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Verge Labs (formerly Verge Genomics) is a San Francisco-based private AI company building all-in-human foundation models for neuroscience drug development. Its core platform, Converge, is trained on what the company describes as one of the largest proprietary multi-modal neuroscience patient datasets in the world — deep molecular profiling on 12,000+ brains across 6,000 patients with paired proteomic, genomic, and clinical data, plus a physical inventory of 900+ frozen brain tissue samples. On top of this data, the company has built the vBx foundation model, which generates a "virtual biopsy" of the brain from routine blood draws and predicts therapy response and side effects with claimed 3x greater accuracy than prior state-of-the-art models.

The company's go-to-market is enterprise B2B: it monetizes its dataset and models through direct strategic partnerships with top-20 pharmaceutical companies, including Eli Lilly, AstraZeneca, and Merck, supporting target discovery, target characterization, biomarker identification, and patient stratification. Verge also reports $1.6 billion in cumulative partnership value, 280+ surfaced novel drug targets, and an 83% preclinical validation rate. Originally a drug developer that took VRG50635 (an AI-designed ALS candidate) into the clinic, the company terminated that program in December 2025 after a Phase 1 efficacy miss and subsequently laid off approximately 90% of its workforce, rebranded as Verge Labs, and pivoted to providing AI-powered data services to drug developers rather than developing drugs internally. Total disclosed funding is approximately $130 million, including a $98 million Series B in 2021 led by BlackRock with Eli Lilly and Merck GHI, and a $32 million round in February 2025.

Short descriptiontext

Verge Labs (formerly Verge Genomics) builds AI foundation models for neuroscience drug development, trained on proprietary multi-modal brain tissue and clinical data from 12,000+ patients, and sells target discovery, biomarker, and patient stratification services to top-20 pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, precision neurology AI, neuroscience data platform, clinical trial optimization, genomics target identification
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHDAAACAA
Foundation Model Developers (LLM/Multimodal Model Labs)
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI-Powered Data Services
TypeData Monetisation
Description

Providing AI-powered data services to drug developers including identifying drug targets, finding patients, and predicting biomarkers. Business model centered on monetizing datasets and insights.

biopharmadive.com
2Partnership Agreements with Pharma
TypeSubscription Recurring
Description

Strategic partnerships with pharmaceutical companies for drug discovery and development, including collaborations with top-20 pharma companies.

vcnewsdaily.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Verge Labs provides AI-powered drug discovery and data services to pharmaceutical partners using its Converge machine learning platform and vBx multi-modal foundation model. The platform leverages a proprietary dataset of 12,000+ profiled brains and 900+ frozen tissue samples to deliver target discovery, target characterization, biomarker identification, and patient stratification. Customers access these capabilities through strategic collaboration agreements focused on neuroscience drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 43% reduction in required patient enrollment for clinical trials using vBx-1.0
+3 more records
Product overview1 text field

Verge Labs (formerly Verge Genomics) offers an AI-powered drug discovery platform centered on its Converge machine learning platform and vBx foundation model. The platform leverages one of the world's largest proprietary multi-modal neuroscience patient datasets (12,000+ brains across 6,000 patients) to build foundation models that reason about neurological disease at the patient level. The company provides AI-powered services to drug developers including target discovery, target characterization, biomarker identification, and patient stratification. After terminating its sole clinical candidate VRG50635 in late 2025 following Phase 1 trial failure, the company pivoted to focus on providing AI-powered data services to drug developers, monetizing datasets and insights rather than developing drugs independently.

Product and service3 records
1vBx Foundation Model
CategoryAI Foundation Model
Description

Multi-modal foundation model for precision neurology that predicts brain activity, therapy response, and side effects in patients with up to 3x greater accuracy than previous state-of-the-art models. Generates a virtual biopsy of the brain from routine blood draws. Sold to drug developers and pharmaceutical partners for clinical trial optimization and patient stratification.

2Converge Platform
CategoryDrug Discovery Platform
Description

Machine learning platform for drug discovery using proprietary multimodal patient brain data. Enables target discovery, target characterization, biomarker identification, and patient stratification for pharmaceutical and biotech partners.

3VRG201 Development Candidate
CategoryClinical Candidate
Description

AI-discovered drug development candidate in Verge's pipeline, representing one of two AI-discovered drugs that reached clinical candidate stage. Targeted at neurological disease indications.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-11-20
Description

Active collaboration with Lilly to discover and develop novel treatments for ALS using Verge's AI platform. Lilly is developing ALS therapeutics against targets identified through the Verge technology platform.

2Ferrer (Spanish pharma)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

In March 2024, Verge entered a licensing deal with Ferrer worth up to 112.5 million euros for ex-U.S. rights to VRG50635 ALS treatment. The deal is now in limbo following Verge's termination of the clinical asset.

fiercebiotech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI platform for patient stratification and drug development with pharma partners; overlapping biomarker and trial-optimization use cases, focused on oncology as well as other indications.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning; most direct comparable in business model, target ID, and pharma partnerships.

TypeDirect peer
Description

Machine learning-driven drug discovery combining patient-derived data with ML; comparable platform play with pharma partnerships and disease-specific focus.

TypeDirect peer
Description

AI-driven small molecule drug discovery with multiple pharma collaborations; directly comparable AI-bio platform and partnership economics.

TypeDirect peer
Description

AI foundation model applied to drug discovery with pharma partnerships; comparable target ID and clinical development positioning.

TypeDirect peer
Description

AI-based small molecule discovery with pharma partnerships; comparable B2B pharma services and foundation-model approach.

7Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery spinout building foundation models (AlphaFold) for pharma; broader scope and deeper capital base, but same fundamental play of applying large ML models to drug development.

TypeBroad incumbent
Description

Physics-based computational chemistry and ML platform serving pharma; broader portfolio of software, services, and internal pipeline, comparable as an incumbent informatics vendor.

9Tempus Labs
TypeBroad incumbent
Description

Multi-modal patient data and AI platform with strong pharma services business; competing for data-monetization budgets and biomarker workstreams at scale.

TypeOthers
Description

Precision medicine company combining computational methods with drug development; adjacent rather than directly competitive, but comparable in marrying computation with clinical pipeline ambition.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Verge Genomics

AI Drug Discovery Platformvergegenomics.com

Verge Labs (formerly Verge Genomics) builds AI foundation models for neuroscience drug development, trained on proprietary multi-modal brain tissue and clinical data from 12,000+ patients, and sells target discovery, biomarker, and patient stratification services to top-20 pharmaceutical companies.

What Verge Genomics does

Verge Labs (formerly Verge Genomics) is a San Francisco-based private AI company building all-in-human foundation models for neuroscience drug development. Its core platform, Converge, is trained on what the company describes as one of the largest proprietary multi-modal neuroscience patient datasets in the world — deep molecular profiling on 12,000+ brains across 6,000 patients with paired proteomic, genomic, and clinical data, plus a physical inventory of 900+ frozen brain tissue samples. On top of this data, the company has built the vBx foundation model, which generates a "virtual biopsy" of the brain from routine blood draws and predicts therapy response and side effects with claimed 3x greater accuracy than prior state-of-the-art models.

The company's go-to-market is enterprise B2B: it monetizes its dataset and models through direct strategic partnerships with top-20 pharmaceutical companies, including Eli Lilly, AstraZeneca, and Merck, supporting target discovery, target characterization, biomarker identification, and patient stratification. Verge also reports $1.6 billion in cumulative partnership value, 280+ surfaced novel drug targets, and an 83% preclinical validation rate. Originally a drug developer that took VRG50635 (an AI-designed ALS candidate) into the clinic, the company terminated that program in December 2025 after a Phase 1 efficacy miss and subsequently laid off approximately 90% of its workforce, rebranded as Verge Labs, and pivoted to providing AI-powered data services to drug developers rather than developing drugs internally. Total disclosed funding is approximately $130 million, including a $98 million Series B in 2021 led by BlackRock with Eli Lilly and Merck GHI, and a $32 million round in February 2025.

Verge Genomics firmographics

Firmographics
Name
Verge Genomics
Legal name
Verge Labs
Website
https://vergegenomics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Verge Labs (formerly Verge Genomics) builds AI foundation models for neuroscience drug development, trained on proprietary multi-modal brain tissue and clinical data from 12,000+ patients, and sells target discovery, biomarker, and patient stratification services to top-20 pharmaceutical companies.
Ownership category
akta.pro rank

Verge Genomics industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHDAAACAA
Foundation Model Developers (LLM/Multimodal Model Labs)
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)

Keywords

  • AI drug discovery
  • Precision neurology AI
  • Neuroscience data platform
  • Clinical trial optimization
  • Genomics target identification

Where Verge Genomics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Verge Genomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. AI-Powered Data Services: Providing AI-powered data services to drug developers including identifying drug targets, finding patients, and predicting biomarkers. Business model centered on monetizing datasets and insights.
  2. Partnership Agreements with Pharma: Strategic partnerships with pharmaceutical companies for drug discovery and development, including collaborations with top-20 pharma companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Verge Genomics product offering

Product offering

Core offering

Verge Labs provides AI-powered drug discovery and data services to pharmaceutical partners using its Converge machine learning platform and vBx multi-modal foundation model. The platform leverages a proprietary dataset of 12,000+ profiled brains and 900+ frozen tissue samples to deliver target discovery, target characterization, biomarker identification, and patient stratification. Customers access these capabilities through strategic collaboration agreements focused on neuroscience drug development.

Product overview

Verge Labs (formerly Verge Genomics) offers an AI-powered drug discovery platform centered on its Converge machine learning platform and vBx foundation model. The platform leverages one of the world's largest proprietary multi-modal neuroscience patient datasets (12,000+ brains across 6,000 patients) to build foundation models that reason about neurological disease at the patient level. The company provides AI-powered services to drug developers including target discovery, target characterization, biomarker identification, and patient stratification. After terminating its sole clinical candidate VRG50635 in late 2025 following Phase 1 trial failure, the company pivoted to focus on providing AI-powered data services to drug developers, monetizing datasets and insights rather than developing drugs independently.

Differentiator

Problem solved

Functional benefit

Products and services

  • vBx Foundation Model Multi-modal foundation model for precision neurology that predicts brain activity, therapy response, and side effects in patients with up to 3x greater accuracy than previous state-of-the-art models. Generates a virtual biopsy of the brain from routine blood draws. Sold to drug developers and pharmaceutical partners for clinical trial optimization and patient stratification.
  • Converge Platform Machine learning platform for drug discovery using proprietary multimodal patient brain data. Enables target discovery, target characterization, biomarker identification, and patient stratification for pharmaceutical and biotech partners.
  • VRG201 Development Candidate AI-discovered drug development candidate in Verge's pipeline, representing one of two AI-discovered drugs that reached clinical candidate stage. Targeted at neurological disease indications.

Quantifiable outcome

  • 43% reduction in required patient enrollment for clinical trials using vBx-1.0
  • +3 more outcomes

Companies that use Verge Genomics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Verge Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Verge Genomics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major.

  • Eli Lilly (Collaboration)majorStrategic or Co-development Partner · 20 November 2024Active collaboration with Lilly to discover and develop novel treatments for ALS using Verge's AI platform. Lilly is developing ALS therapeutics against targets identified through the Verge technology platform.
  • Ferrer (Spanish pharma)majorStrategic or Co-development PartnerIn March 2024, Verge entered a licensing deal with Ferrer worth up to 112.5 million euros for ex-U.S. rights to VRG50635 ALS treatment. The deal is now in limbo following Verge's termination of the clinical asset.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Verge Genomics competitors and assessment

Company assessment

Emerging players

  • Owkin: AI platform for patient stratification and drug development with pharma partners; overlapping biomarker and trial-optimization use cases, focused on oncology as well as other indications.

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning; most direct comparable in business model, target ID, and pharma partnerships.
  • Insitro: Machine learning-driven drug discovery combining patient-derived data with ML; comparable platform play with pharma partnerships and disease-specific focus.
  • Exscientia: AI-driven small molecule drug discovery with multiple pharma collaborations; directly comparable AI-bio platform and partnership economics.
  • BenevolentAI: AI foundation model applied to drug discovery with pharma partnerships; comparable target ID and clinical development positioning.
  • Atomwise: AI-based small molecule discovery with pharma partnerships; comparable B2B pharma services and foundation-model approach.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery spinout building foundation models (AlphaFold) for pharma; broader scope and deeper capital base, but same fundamental play of applying large ML models to drug development.
  • Schrödinger: Physics-based computational chemistry and ML platform serving pharma; broader portfolio of software, services, and internal pipeline, comparable as an incumbent informatics vendor.
  • Tempus Labs: Multi-modal patient data and AI platform with strong pharma services business; competing for data-monetization budgets and biomarker workstreams at scale.

Others

  • Relay Therapeutics: Precision medicine company combining computational methods with drug development; adjacent rather than directly competitive, but comparable in marrying computation with clinical pipeline ambition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Verge Genomics social profiles

Digital presence

Verge Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Verge Genomics leadership team

Management profile

Number of profiles

Profiles10 records

Verge Genomics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Verge Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verge Genomics

What does Verge Genomics do?

Verge Labs provides AI-powered drug discovery and data services to pharmaceutical partners using its Converge machine learning platform and vBx multi-modal foundation model. The platform leverages a proprietary dataset of 12,000+ profiled brains and 900+ frozen tissue samples to deliver target discovery, target characterization, biomarker identification, and patient stratification. Customers access these capabilities through strategic collaboration agreements focused on neuroscience drug development.

Is Verge Genomics a public or private company?

Verge Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Verge Genomics founded?

Verge Genomics was founded in 2015. It employs 11 to 50 people.

Where is Verge Genomics based?

Verge Genomics is headquartered in San Francisco, United States, in the North America region.

How does Verge Genomics make money?

Two revenue lines are on record. AI-Powered Data Services are the primary driver. The others are partnership Agreements with Pharma.

Who are Verge Genomics's main competitors?

Owkin is listed as an emerging player. Direct peers are Recursion Pharmaceuticals, Insitro, Exscientia, BenevolentAI and Atomwise. Broad incumbents are Isomorphic Labs, Schrödinger and Tempus Labs. Relay Therapeutics is listed as an others.

Does Verge Genomics have an API?

No public API is recorded for Verge Genomics.

What industry is Verge Genomics in?

Verge Genomics's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldLilly taps Verge Genomics AI-driven discovery platform in new multiyear dealEli Lilly and Co. agreed to pay Verge Genomics $25 million in up-front, equity, and potential near-term payments, plus up to $694 million in milestones, for a three-year collaboration to discover and validate up to four new ALS targets. Verge retained rights to its internal lead ALS program, poised to enter the clinic next year.BioPharma DiveVerge, following trial failure, rebrands its AI drug discovery ambitionsVerge Genomics is rebranding as Verge Labs and pivoting to provide AI-powered data services to drug developers after its experimental AI-designed drug VRG50635 for ALS failed an early-stage clinical trial, prompting approximately 90% workforce layoffs. The company will continue neuroscience research by partnering with developers to identify drug targets, find patients, and predict biomarkers, with a business model centered on monetizing datasets and insights. CEO Alice Zhang framed the setback as a normal part of technological innovation, noting that transformational technologies rarely succeed on the first attempt.Longevity.TechnologyNew AI research reshapes neuroprotective drug discovery fundingBCC Research published a Pulse report titled "AI Impact on Neuroprotective Agents" forecasting the North American neuroprotective agents market to grow at approximately 4.5% CAGR through 2030, with hundreds of millions flowing into AI-driven neuroscience startups. The research documents intensifying pharma-tech collaborations including Eli Lilly's partnership with NVIDIA to build an AI supercomputer, a $200 million joint venture between MeiraGTx and Hologen, and Biogen's work with TheraPanacea, while identifying recent venture raises by Nilo Therapeutics, Verge Genomics, Chai Discovery, NRG Therapeutics, BEXORG, and Illimis Therapeutics. The report frames these developments as creating new investor opportunities and describes AI deployment across the drug discovery value chain from target identification to precision dosing.FierceBiotechVerge Genomics drops sole clinical candidate in return to AI drug discovery rootsVerge Genomics is discontinuing its only clinical candidate, VRG50635, after it failed an efficacy analysis in a phase 1 trial and will return to its AI drug discovery focus. The decision leaves a licensing agreement with Ferrer regarding the asset in uncertainty, with the deal originally valued at over 112.5 million euros. Verge plans to refocus on its machine learning drug discovery platform, Converge, to enhance pipeline success rates and achieve profitability.The National Law ReviewVerge Genomics to Auction AI and Genomics Drug Discovery Assets vVerge Genomics will auction its AI and genomics drug discovery assets via Silicon Valley Disposition, with the online auction opening October 21 at 10am PST. Featured items include BioTek Cytation 5, Agilent Seahorse Analyzer, and Applied Biosystems QuantStudio 5 PCR systems.EIN PresswireVerge Genomics to Auction AI and Genomics Drug Discovery Assets via Silicon Valley Disposition (SVD)Silicon Valley Disposition (SVD) will conduct an online auction of Verge Genomics' laboratory assets from October 21–23, 2025, in South San Francisco, California. Verge Genomics was a biotech company that combined machine learning with human genomics to accelerate drug discovery. The auction features over 50 lots of biotech and R&D instruments from brands including Molecular Devices, BioTek, Agilent, Applied Biosystems, Cytiva, Promega, Eppendorf, and Zeiss.AInvestAI in Healthcare: The Disruptive Force Redefining Medicine and InvestmentAI-driven tools for early detection of Parkinson's and Alzheimer's are advancing, with companies like Verge Genomics and IGC Pharma using genomic and acoustic biomarkers. The WHO estimates delaying Alzheimer's onset by two years could cut global healthcare costs by 40%, and FDA approvals are accelerating adoption. Investors are advised to target firms with proprietary algorithms and regulatory traction.BioPharmaTrendBeyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and BeyondThe article proposes a qualitative framework for classifying AI-driven drug discovery (AIDD) companies based on four key attributes: holistic biological focus, robust software platforms, data acquisition priority, and technology validation. It contrasts modern AIDD with legacy computational tools by highlighting the shift from reductionist methods to systems biology approaches using multimodal data and generative AI. The report details how leading firms like Insilico Medicine, Recursion, and Verge Genomics are building comprehensive platforms to accelerate drug discovery through integrated wet-lab and dry-lab workflows.